Healthcare and the Climate Imperative
The healthcare industry occupies a unique position in the global sustainability landscape. On one hand, its mission โ to improve health and save lives โ is inherently aligned with the well-being of people and communities. On the other hand, the sectorโs environmental footprint is substantial: healthcare accounts for approximately 4.4% of global net carbon emissions, consumes vast quantities of water and energy, and generates significant amounts of waste, including single-use plastics and pharmaceutical residues.
For a biopharmaceutical company like GSK, the imperative to operate sustainably is both a moral responsibility and a business necessity. Patients, employees, investors, and regulators increasingly expect companies to demonstrate that they can deliver innovative medicines and vaccines while minimising their impact on the planet. GSK has responded to this challenge with an ambitious environmental sustainability strategy that addresses carbon emissions, water stewardship, biodiversity, and circular economy principles across its global operations.
GSKโs Net Zero Ambition
GSK has committed to achieving net zero carbon emissions across its entire value chain by 2045, with an interim target of a 80% reduction in Scope 1 and 2 emissions by 2030, from a 2020 baseline. These targets are aligned with the Paris Agreementโs goal of limiting global warming to 1.5ยฐC and have been validated by the Science Based Targets initiative (SBTi).
Key elements of GSKโs decarbonisation strategy include:
- Renewable energy: GSK has transitioned to 100% renewable electricity at its manufacturing and R&D sites across multiple countries, with plans to extend this to all global operations.
- Energy efficiency: Investments in building management systems, process optimisation, and equipment upgrades are reducing energy consumption across the companyโs manufacturing network.
- Green chemistry: GSKโs R&D teams are pioneering solvent-free synthesis routes, catalytic processes, and biocatalysis techniques that reduce the environmental impact of drug manufacturing.
- Sustainable supply chain: GSK is working with suppliers to reduce Scope 3 emissions through sustainable sourcing, logistics optimisation, and collaborative emission-reduction programmes.
Transforming the Inhaler: A Case Study in Sustainable Innovation
One of the most visible examples of GSKโs sustainability commitment is the effort to reduce the carbon footprint of respiratory inhalers. Metered-dose inhalers (MDIs), which are used by millions of patients worldwide for conditions including asthma and COPD, rely on hydrofluorocarbon (HFC) propellants that are potent greenhouse gases. A single MDI can have a carbon footprint equivalent to a 280-kilometre car journey.
GSK is investing in next-generation propellant technology that could reduce the carbon footprint of MDIs by up to 90%, while maintaining the same drug delivery performance that patients and clinicians rely on. In parallel, the company is supporting inhaler recycling programmes that recover and destroy residual propellants, preventing their release into the atmosphere. These efforts reflect a commitment to sustainability that does not compromise patient care โ ensuring that people with respiratory conditions continue to have access to the treatments they need.
Water, Waste, and Biodiversity
GSKโs environmental strategy extends beyond carbon emissions to encompass water stewardship, waste reduction, and biodiversity protection. The company has set targets to reduce water consumption in water-stressed regions, eliminate waste to landfill from its manufacturing operations, and protect and enhance biodiversity on and around its sites.
Notable initiatives include:
- Water recycling: Advanced water treatment and recycling systems at manufacturing sites in water-stressed regions have significantly reduced freshwater consumption.
- Zero waste to landfill: Multiple GSK manufacturing sites have achieved zero waste to landfill certification, with waste diverted to recycling, recovery, or energy-from-waste facilities.
- Biodiversity enhancement: GSK has partnered with conservation organisations to implement biodiversity action plans at key sites, including habitat restoration, pollinator support, and environmental education programmes for employees and local communities.
Embedding Sustainability in the Value Chain
True sustainability requires action not only within a companyโs own operations but across its entire value chain. GSK engages with raw material suppliers, contract manufacturers, logistics providers, and packaging companies to drive environmental improvements throughout the product lifecycle. The companyโs Responsible Business programme includes supplier sustainability assessments, collaborative improvement initiatives, and preferential sourcing from suppliers that demonstrate strong environmental performance.
A Sustainable Future for Healthcare
Building a sustainable healthcare system is not a choice between health and the environment โ it is about recognising that the two are inextricably linked. Climate change, biodiversity loss, and environmental pollution are themselves major drivers of disease, from respiratory illness to vector-borne infections. By operating sustainably, GSK is not only reducing its environmental footprint but actively contributing to the prevention of the diseases it seeks to treat. This is sustainability in its truest sense: protecting the health of people and the planet, together.